The global Human Microbiome market size is predicted to grow from US$ 556 million in 2025 to US$ 1880 million in 2031; it is expected to grow at a CAGR of 22.5% from 2025 to 2031.
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that"s 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.
The 鈥淗uman Microbiome Industry Forecast鈥� looks at past sales and reviews total world Human Microbiome sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Microbiome sales for 2025 through 2031. With Human Microbiome sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Microbiome industry.
This Insight Report provides a comprehensive analysis of the global Human Microbiome landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Human Microbiome portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Human Microbiome market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Microbiome and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Microbiome.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Microbiome market by product type, application, key players and key regions and countries.
Segmentation by Type:
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Others
Segmentation by Application:
Treatment
Diagnosis
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Human Microbiome 麻豆原创 Size (2020-2031)
2.1.2 Human Microbiome 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Human Microbiome by Country/Region (2020, 2024 & 2031)
2.2 Human Microbiome Segment by Type
2.2.1 Gastrointestinal Tract Human Micobiome
2.2.2 Urogenital Tract Human Micobiome
2.2.3 Others
2.3 Human Microbiome 麻豆原创 Size by Type
2.3.1 Human Microbiome 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Human Microbiome 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Human Microbiome Segment by Application
2.4.1 Treatment
2.4.2 Diagnosis
2.5 Human Microbiome 麻豆原创 Size by Application
2.5.1 Human Microbiome 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Human Microbiome 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Human Microbiome 麻豆原创 Size by Player
3.1 Human Microbiome 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Human Microbiome Revenue by Player (2020-2025)
3.1.2 Global Human Microbiome Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Human Microbiome Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Human Microbiome by Region
4.1 Human Microbiome 麻豆原创 Size by Region (2020-2025)
4.2 Global Human Microbiome Annual Revenue by Country/Region (2020-2025)
4.3 Americas Human Microbiome 麻豆原创 Size Growth (2020-2025)
4.4 APAC Human Microbiome 麻豆原创 Size Growth (2020-2025)
4.5 Europe Human Microbiome 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Human Microbiome 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Human Microbiome 麻豆原创 Size by Country (2020-2025)
5.2 Americas Human Microbiome 麻豆原创 Size by Type (2020-2025)
5.3 Americas Human Microbiome 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Microbiome 麻豆原创 Size by Region (2020-2025)
6.2 APAC Human Microbiome 麻豆原创 Size by Type (2020-2025)
6.3 APAC Human Microbiome 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Human Microbiome 麻豆原创 Size by Country (2020-2025)
7.2 Europe Human Microbiome 麻豆原创 Size by Type (2020-2025)
7.3 Europe Human Microbiome 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Microbiome by Region (2020-2025)
8.2 Middle East & Africa Human Microbiome 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Human Microbiome 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Human Microbiome 麻豆原创 Forecast
10.1 Global Human Microbiome Forecast by Region (2026-2031)
10.1.1 Global Human Microbiome Forecast by Region (2026-2031)
10.1.2 Americas Human Microbiome Forecast
10.1.3 APAC Human Microbiome Forecast
10.1.4 Europe Human Microbiome Forecast
10.1.5 Middle East & Africa Human Microbiome Forecast
10.2 Americas Human Microbiome Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Human Microbiome Forecast
10.2.2 Canada 麻豆原创 Human Microbiome Forecast
10.2.3 Mexico 麻豆原创 Human Microbiome Forecast
10.2.4 Brazil 麻豆原创 Human Microbiome Forecast
10.3 APAC Human Microbiome Forecast by Region (2026-2031)
10.3.1 China Human Microbiome 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Human Microbiome Forecast
10.3.3 Korea 麻豆原创 Human Microbiome Forecast
10.3.4 Southeast Asia 麻豆原创 Human Microbiome Forecast
10.3.5 India 麻豆原创 Human Microbiome Forecast
10.3.6 Australia 麻豆原创 Human Microbiome Forecast
10.4 Europe Human Microbiome Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Human Microbiome Forecast
10.4.2 France 麻豆原创 Human Microbiome Forecast
10.4.3 UK 麻豆原创 Human Microbiome Forecast
10.4.4 Italy 麻豆原创 Human Microbiome Forecast
10.4.5 Russia 麻豆原创 Human Microbiome Forecast
10.5 Middle East & Africa Human Microbiome Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Human Microbiome Forecast
10.5.2 South Africa 麻豆原创 Human Microbiome Forecast
10.5.3 Israel 麻豆原创 Human Microbiome Forecast
10.5.4 Turkey 麻豆原创 Human Microbiome Forecast
10.6 Global Human Microbiome Forecast by Type (2026-2031)
10.7 Global Human Microbiome Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Human Microbiome Forecast
11 Key Players Analysis
11.1 Vedanta
11.1.1 Vedanta Company Information
11.1.2 Vedanta Human Microbiome Product Offered
11.1.3 Vedanta Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Vedanta Main Business Overview
11.1.5 Vedanta Latest Developments
11.2 Seres Therapeutics
11.2.1 Seres Therapeutics Company Information
11.2.2 Seres Therapeutics Human Microbiome Product Offered
11.2.3 Seres Therapeutics Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Seres Therapeutics Main Business Overview
11.2.5 Seres Therapeutics Latest Developments
11.3 Second Genome
11.3.1 Second Genome Company Information
11.3.2 Second Genome Human Microbiome Product Offered
11.3.3 Second Genome Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Second Genome Main Business Overview
11.3.5 Second Genome Latest Developments
11.4 Rebiotix
11.4.1 Rebiotix Company Information
11.4.2 Rebiotix Human Microbiome Product Offered
11.4.3 Rebiotix Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Rebiotix Main Business Overview
11.4.5 Rebiotix Latest Developments
11.5 ActoGeniX
11.5.1 ActoGeniX Company Information
11.5.2 ActoGeniX Human Microbiome Product Offered
11.5.3 ActoGeniX Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 ActoGeniX Main Business Overview
11.5.5 ActoGeniX Latest Developments
11.6 Enterome BioScience
11.6.1 Enterome BioScience Company Information
11.6.2 Enterome BioScience Human Microbiome Product Offered
11.6.3 Enterome BioScience Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Enterome BioScience Main Business Overview
11.6.5 Enterome BioScience Latest Developments
11.7 AvidBiotics
11.7.1 AvidBiotics Company Information
11.7.2 AvidBiotics Human Microbiome Product Offered
11.7.3 AvidBiotics Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 AvidBiotics Main Business Overview
11.7.5 AvidBiotics Latest Developments
11.8 4D Pharma Research Ltd
11.8.1 4D Pharma Research Ltd Company Information
11.8.2 4D Pharma Research Ltd Human Microbiome Product Offered
11.8.3 4D Pharma Research Ltd Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 4D Pharma Research Ltd Main Business Overview
11.8.5 4D Pharma Research Ltd Latest Developments
11.9 Enterologics
11.9.1 Enterologics Company Information
11.9.2 Enterologics Human Microbiome Product Offered
11.9.3 Enterologics Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Enterologics Main Business Overview
11.9.5 Enterologics Latest Developments
11.10 Metabogen
11.10.1 Metabogen Company Information
11.10.2 Metabogen Human Microbiome Product Offered
11.10.3 Metabogen Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Metabogen Main Business Overview
11.10.5 Metabogen Latest Developments
11.11 Metabiomics
11.11.1 Metabiomics Company Information
11.11.2 Metabiomics Human Microbiome Product Offered
11.11.3 Metabiomics Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Metabiomics Main Business Overview
11.11.5 Metabiomics Latest Developments
11.12 Ritter Pharmaceuticals
11.12.1 Ritter Pharmaceuticals Company Information
11.12.2 Ritter Pharmaceuticals Human Microbiome Product Offered
11.12.3 Ritter Pharmaceuticals Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Ritter Pharmaceuticals Main Business Overview
11.12.5 Ritter Pharmaceuticals Latest Developments
11.13 Osel
11.13.1 Osel Company Information
11.13.2 Osel Human Microbiome Product Offered
11.13.3 Osel Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Osel Main Business Overview
11.13.5 Osel Latest Developments
11.14 Symberix
11.14.1 Symberix Company Information
11.14.2 Symberix Human Microbiome Product Offered
11.14.3 Symberix Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Symberix Main Business Overview
11.14.5 Symberix Latest Developments
11.15 Miomics
11.15.1 Miomics Company Information
11.15.2 Miomics Human Microbiome Product Offered
11.15.3 Miomics Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Miomics Main Business Overview
11.15.5 Miomics Latest Developments
11.16 Symbiotix Biotherapies
11.16.1 Symbiotix Biotherapies Company Information
11.16.2 Symbiotix Biotherapies Human Microbiome Product Offered
11.16.3 Symbiotix Biotherapies Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Symbiotix Biotherapies Main Business Overview
11.16.5 Symbiotix Biotherapies Latest Developments
11.17 MicroBiome Therapeutics LLC
11.17.1 MicroBiome Therapeutics LLC Company Information
11.17.2 MicroBiome Therapeutics LLC Human Microbiome Product Offered
11.17.3 MicroBiome Therapeutics LLC Human Microbiome Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 MicroBiome Therapeutics LLC Main Business Overview
11.17.5 MicroBiome Therapeutics LLC Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
